Lupin Ltd. (LUPIN) fundamentals
Lupin Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as LUPIN (ISIN INE326A01037). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Lupin Ltd. does
Lupin Limited is a global pharmaceutical company, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates in India and the United States across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti-Inflammatory Drug therapy segments and operates in the Anti-TB and Cephalosporins segments. Its generic formulations include Filgrastim, Peg filgrastim, Etanercept and Albuterol. Its diabetes brands include Gibtulio, Ajaduo, Gibtulio Met, ONDERO and ONDERO MET. Its other brands include AntaGolin, RyChol and others. Its Huminsulin range of products includes Insulin Human.
Valuation and market data
| Last close | ₹1959.90 |
|---|---|
| Market capitalisation | ₹89,903 crore |
| Enterprise value | ₹88,936 crore |
| P/E (TTM) | 16.79 |
| Price to book | 3.99 |
| Price to sales (TTM) | 1.77 |
| Book value per share | ₹490.79 |
| Dividend yield | 91.84% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Sep 10 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹29,039 crore | ₹6,873 crore | ₹5,355 crore | 116.75 |
| Mar 2025 | ₹22,910 crore | ₹4,015 crore | ₹3,306 crore | 71.95 |
| Mar 2024 | ₹20,142 crore | ₹2,422 crore | ₹1,936 crore | 42.05 |
| Mar 2023 | ₹16,793 crore | ₹716 crore | ₹448 crore | 9.46 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 46.8% |
|---|---|
| Foreign institutions (FII) | 23.3% |
| Mutual funds | 14.6% |
| Other domestic institutions | 9.2% |
| Retail and others | 6.1% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.